Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.69 |
| ▸ | RXRB | P28702 | 2/20 | 0.69 |
| ▸ | RXRG | P48443 | 2/20 | 0.69 |
| ▸ | MAOB | P27338 | 7/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL27542849 | 0.95 | RXRA (0.68) | RXRARXRBRXRGMAOBNR4A2 | |
| SCHEMBL27858340 | 0.92 | RXRA (0.64) | RXRARXRBRXRGMAOBNR4A2 | |
| SCHEMBL11959143 | 0.89 | MAOB (0.72) | RXRARXRBRXRGMAOBNR4A2 | |
| SCHEMBL1268719 | 0.86 | MAOB (0.81) | MAOBNR4A2CYP1A2CYP2C19CYP4F2 | |
| SCHEMBL6355348 | 0.85 | CTSV (0.58) | RXRARXRBRXRGMAOBNR4A2 | |
| SCHEMBL27676289 | 0.85 | RXRA (0.69) | RXRARXRBRXRGMAOBNR4A2 | |
| SCHEMBL1842452 | 0.84 | MEN1 (0.59) | RXRARXRBRXRGMAOBCYP1A2 | |
| SCHEMBL4933216 | 0.84 | MRGPRX4 (0.63) | RXRARXRBRXRGMAOBCYP1A2 | |
| Methyl Alcohol SCHEMBL9626623 | 0.84 | RXRA (0.68) | RXRARXRBRXRGMAOBNR4A2 | |
| SCHEMBL21944885 | 0.84 | NR4A2 (0.61) | RXRARXRBRXRGMAOBNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119080710-A | Meta-hydroxylamine bitartrate impurity, synthesis method and application | 上海现代哈森（商丘）药业有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-119080710-A | Meta-hydroxylamine bitartrate impurity, synthesis method and application | 上海现代哈森（商丘）药业有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-112041165-A | Additive manufacturing using photothermal dyes for high efficiency sintering | 株式会社理光 | 2020-12-04 | — | — | CN | disclosed |
| CN-101432277-B | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | LILLY CO ELI | 2013-12-25 | — | — | CN | disclosed |
| CN-101454310-B | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | LILLY CO ELI | 2013-07-17 | — | — | CN | disclosed |
| CN-101426780-B | Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | LILLY CO ELI | 2013-06-26 | — | — | CN | disclosed |
| WO-2012073249-A1 | A NOVEL PROCESS FOR THE PREPARATION OF 3-(BENZYLOXY)- BENZENETHIOL, A KEY INTERMEDIATE FOR THE PREPARATION OF PHARMACEUTICAL DRUGS. | ARCH PHARMALABS LIMITED (IN) | 2012-06-07 | — | — | WO | disclosed |
| CN-101432265-B | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND CO. (US) | 2011-12-14 | — | — | CN | disclosed |
| WO-2009109648-A1 | PROCESS FOR PREPARING COMPOUNDS CONTAINING A HYDRONAPHTALENE STRUCTURE WITH AN UNSYMMETRICALLY SUBSTITUTED BENZENE RING | SOLVIAS AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| EP-2098511-A1 | Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring | Solvias AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| CN-101454310-A | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | LILLY CO ELI (US) | 2009-06-10 | — | — | CN | disclosed |
| CN-101432265-A | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | LILLY CO ELI (US) | 2009-05-13 | — | — | CN | disclosed |
| EP-2044038-A2 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Cornerstone Therapeutics Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007146066-A2 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CRITICAL THERAPEUTICS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1312605-B1 | Method for producing biaryl compounds | SUMITOMO CHEMICAL CO (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-7122711-B2 | Method for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20030158419-A1 | Method for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-08-21 | — | — | US | disclosed |
| EP-1312605-A1 | Method for producing biaryl compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | GABRA5, GABRA4, GABRA3 | RXRA 502/4885RXRB 310/4885RXRG 569/4885 |
| US-20030158419-A1 | Method for producing biaryl compound | B2M, BMI1, CYP2W1 | RXRA 385/4885RXRB 442/4885RXRG 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.